Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
NCT ID: NCT00130260
Last Updated: 2008-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
99 participants
INTERVENTIONAL
2005-08-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
NCT00071214
Evaluation of Manufacturing Lot of StaphVAX
NCT00211900
StaphVAX Immunogenicity in Orthopedic Implant Patients
NCT00211926
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
NCT02804711
Evaluation of Consistency of StaphVAX Manufacturing Lots
NCT00211991
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vaccine, schedule 1
3rd and 4th dose of vaccine, on original schedule
Staph aureus types 5 and 8 conjugate vaccine
each IM dose contains 200 mc total conjugate
vaccine, schedule 2
3rd and 4th dose of vaccine on modified schedule
Staph aureus types 5 and 8 conjugate vaccine
each IM dose contains 200 mc total conjugate
placebo, schedule 1
3rd and 4th dose of placebo, on original schedule
placebo
placebo to match StaphVAX
placebo, schedule 2
3rd and 4th dose of placebo on modified schedule
placebo
placebo to match StaphVAX
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Staph aureus types 5 and 8 conjugate vaccine
each IM dose contains 200 mc total conjugate
placebo
placebo to match StaphVAX
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
* Negative serum pregnancy test, where appropriate
* Expect to comply with protocol procedures and schedule
Exclusion Criteria
* Immunomodulatory drugs
* Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer)
* Active infection in the 2 weeks prior to study injection
* Serious S. aureus infection within the last 2 months prior to injection
* Hypersensitivity to components of StaphVAX
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nabi Biopharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nabi Biopharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matt Hohenboken, MD, PhD
Role: STUDY_DIRECTOR
Nabi Biopharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
multiple sites: contact Central Study coordination
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Nabi-1372
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.